Overall, our data demonstrate that oncogenic KRAS trigger upregulation of specific AATs (SLC7A5/LAT1, SLC1A5/ASCT2, and SLC38A2/SNAT2) via hippo signaling effector YAP1, leading to mTOR activation and CRC cell proliferation. This evidence concerns the gene KRAS and colorectal carcinoma.